Ocular Hypertension - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 102 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Ocular Hypertension - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ocular Hypertension - Pipeline Review, H1 2015', provides an overview of the Ocular Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on latestage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ocular     Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ocular Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising       pipeline
- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of table 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ocular Hypertension Overview 9
Therapeutics Development 10
Pipeline Products for Ocular Hypertension - Overview 10
Pipeline Products for Ocular Hypertension - Comparative Analysis 11
Ocular Hypertension - Therapeutics under Development by Companies 12
Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes 14
Ocular Hypertension - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Ocular Hypertension - Products under Development by Companies 18
Ocular Hypertension - Products under Investigation by Universities/Institutes 19
Ocular Hypertension - Companies Involved in Therapeutics Development 20
Aerie Pharmaceuticals, Inc. 20
Allergan, Inc. 21
Amakem NV 22
Asahi Kasei Pharma Corp. 23
Bausch & Lomb Incorporated 24
Can-Fite BioPharma Ltd. 25
F. Hoffmann-La Roche Ltd. 26
Inotek Pharmaceuticals Corporation 27
Merck & Co., Inc. 28
Ocular Therapeutix, Inc. 29
Ono Pharmaceutical Co., Ltd. 30
Otsuka Holdings Co., Ltd. 31
Santen Pharmaceutical Co., Ltd. 32
Sylentis S.A. 33
Ocular Hypertension - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(bimatoprost + brimonidine tartrate) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(carteolol hydrochloride + latanoprost) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(dorzolamide hydrochloride + latanoprost) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(latanoprost + trabodenoson) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(tafluprost + timolol maleate) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AMA-0076 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AR-13324 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ATS-8535 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
bamosiran - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bimatoprost SR - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CF-101 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DE-117 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dorzolamide hydrochloride nanoparticle - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
latanoprost - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
latanoprost - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
latanoprost SR - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
latanoprostene bunod - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
lomerizine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ONO-9054 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
OPA-6566 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
RO-5093151 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
tafluprost - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
trabodenoson - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
travoprost SR - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Ocular Hypertension - Recent Pipeline Updates 76
Ocular Hypertension - Dormant Projects 90
Ocular Hypertension - Discontinued Products 92
Ocular Hypertension - Product Development Milestones 94
Featured News & Press Releases 94
Jan 12, 2015: Aerie Pharmaceuticals Announces Acceleration of Expected Timeline for Reporting Efficacy Results from Phase 3 Registration Trial ("Rocket 1") of Rhopressa 94
Nov 25, 2014: Santen Launches TAPCOM Combination Ophthalmic Solution For The Treatment Of Glaucoma And Ocular Hypertension 95
Nov 12, 2014: Ocular Therapeutix Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension 95
Oct 22, 2014: Santen Announces Positive Outcome of the European Decentralized Procedure for Approval of TAPTIQOM 96
Mar 10, 2014: Inotek Pharmaceuticals Initiates Phase 2 Study with Trabodenoson in Combination with Latanoprost for Patients with Glaucoma or Ocular Hypertension 97
Oct 10, 2013: Santen Announces the Launch of TAPROS MINI Ophthalmic Solution 0.0015% for Glaucoma and Ocular Hypertension 98
Sep 20, 2013: Santen Announced Approval for TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension 99
Jun 07, 2013: Zeltia announces that subsidiary Sylentis has attained the primary endpoint of the Phase IIa clinical trial with its compound SYL040012. 99
May 03, 2013: Amakem To Present Additional Data On AMA0076 At ARVO Annual Meeting 100
Jan 18, 2013: Santen Pharma Receives Japanese Approval For Tapros Mini Ophthalmic Solution 0.0015% For Glaucoma And Ocular Hypertension Treatment 100
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102

List of Tables
Number of Products under Development for Ocular Hypertension, H1 2015 10
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Investigation by Universities/Institutes, H1 2015 19
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H1 2015 20
Ocular Hypertension - Pipeline by Allergan, Inc., H1 2015 21
Ocular Hypertension - Pipeline by Amakem NV, H1 2015 22
Ocular Hypertension - Pipeline by Asahi Kasei Pharma Corp., H1 2015 23
Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H1 2015 24
Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H1 2015 25
Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 26
Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H1 2015 27
Ocular Hypertension - Pipeline by Merck & Co., Inc., H1 2015 28
Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H1 2015 29
Ocular Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 30
Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 31
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 32
Ocular Hypertension - Pipeline by Sylentis S.A., H1 2015 33
Assessment by Monotherapy Products, H1 2015 34
Assessment by Combination Products, H1 2015 35
Number of Products by Stage and Target, H1 2015 37
Number of Products by Stage and Mechanism of Action, H1 2015 39
Number of Products by Stage and Route of Administration, H1 2015 41
Number of Products by Stage and Molecule Type, H1 2015 43
Ocular Hypertension Therapeutics - Recent Pipeline Updates, H1 2015 76
Ocular Hypertension - Dormant Projects, H1 2015 90
Ocular Hypertension - Dormant Projects (Contd..1), H1 2015 91
Ocular Hypertension - Discontinued Products, H1 2015 92
Ocular Hypertension - Discontinued Products (Contd..1), H1 2015 93